Colchicine prophylaxis efficacy in PFAPA syndrome: A comparative cohort study

Area of Science:

• Pediatric Rheumatology
• Immunology
• Genetics

Background:

• PFAPA syndrome is the most common periodic fever in children, causing recurrent episodes.
• Current treatments like corticosteroids manage symptoms but don't prevent future attacks or address inflammation.
• Corticosteroids carry potential side effects with long-term use.

Purpose of the Study:

• To evaluate colchicine's effectiveness in preventing PFAPA attacks and extending symptom-free periods.
• To compare colchicine prophylaxis against standard care for PFAPA patients.

Main Methods:

• A retrospective cohort study of 55 pediatric PFAPA patients.
• 15 patients received colchicine prophylaxis; 40 received standard care.
• Primary outcome: change in time between attacks; secondary: FMF genetic status impact.

Main Results:

• Colchicine group showed significantly longer intervals between PFAPA attacks (median 60 days) compared to controls (0 days).
• Colchicine's benefit was observed regardless of FMF (Familial Mediterranean Fever) genetic status.
• Baseline characteristics were similar, but FMF mutation prevalence was higher in the colchicine group.

Conclusions:

• Colchicine prophylaxis is effective in reducing PFAPA attack frequency.
• Benefits are independent of FMF genetic status, supporting its use in diverse PFAPA populations.
• Colchicine represents a shift towards proactive, preventive management for PFAPA, especially for frequent or steroid-sensitive cases.